PIMSH16 Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents


In this lesson, you will learn the required documentation for the MIPS PIMSH# 16 Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center quality measure.

<u>First</u> receipt of high or moderate emetic risk intravenous antineoplastic agent during cycle 1 day 1 of first therapy where:

- <u>Numerator Criteria 1</u>: Patients are administered prior to treatment a fourdrug combination of a neurokinin 1 (NK1) receptor antagonist, a serotonin (5-HT3) receptor antagonist, dexamethasone, and olanzapine
- <u>Numerator Criteria 2</u>: Patients are administered prior to treatment a two-drug combination of a 5-HT3 receptor antagonist, and dexamethasone.


For the purposes of this measure, the following antiemetics would meet the measure:

- Antiemetics administered on the same day as cycle 1 day 1 of the therapy
 OR
- Any new or refill prescription order of antiemetics on the same day as cycle 1 day 1 of the therapy or within 89 days prior to cycle 1 day 1 of the therapy OR
- Any record of antiemetics as active on the medication list within 90 days prior to cycle 1 day 1 of the therapy




- 1. In the Orders tab, go to the Regimens tab.
- 2. Select the diagnosis/problem from the drop-down list.
- 3. Click SEARCH FOR REGIMENS.






4. Select Regimen Type.




5. Respond to therapy and staging inquiries in Clear Value Plus.






- 6. The emetogenic risk level is shown for each regimen.
- 7. Select the desired regimen by clicking on **SELECT**.



- 8. Review and complete any missing data in the Patient Regimen Details box.
- 9. Click OK.






10. The selected regimen of DHAP includes Cisplatin, a high risk emetogenic drug.

To meet the measure numerator, patients receiving a high to moderate risk emetogenic drug are administered either a four-drug combination of a neurokinin 1 (NK1) receptor antagonist, a serotonin (5-HT3) receptor antagonist, dexamethasone, and olanzapine or a two-drug combination of a 5-HT3 receptor antagonist and dexamethasone prior to treatment.



Review the orders to ensure the appropriate premedications have been included.







11. Click SIGN ORDERS.





The ordered premedications can now be seen on the Flowsheet.

This concludes the lesson for the required documentation for the MIPS PIMSH# 16
Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk
Antineoplastic Agents in the Infusion Center quality measure.